Biocompatibility Is Decided by a Risk Process — Not a Default Test Battery.
ISO 10993 strategy for biological evaluation — the endpoints your device actually needs, chosen from how it contacts the body, led by chemical characterization and a biological evaluation plan rather than a reflexive checklist of tests.
How Your Device Touches the Body Decides What You Have to Prove.
ISO 10993-1 categorises devices by the nature and duration of body contact, and that category points to the biological endpoints to consider. The matrix is a starting framework — your evaluation justifies which apply.
The matrix points; the evaluation decides. Modern ISO 10993-1 is risk-based — chemical characterization and toxicological risk assessment increasingly answer endpoints that once meant an animal study. The plan, not the checklist, is the deliverable.
The Modern Biological Evaluation Leads With Chemistry, Not Animals.
ISO 10993-1 is explicit that biological evaluation happens within a risk-management process — you don’t run the full battery reflexively, you evaluate what the device’s materials and contact actually put at risk. Chemical characterization under ISO 10993-18, followed by a toxicological risk assessment, now answers many endpoints that once defaulted to animal testing.
That shift rewards teams who plan. A Biological Evaluation Plan written up front — contact category, materials, existing data, characterization strategy, and the endpoints that genuinely remain — is what regulators want to see, and what turns a scattershot testing spend into a defensible file.
The device's materials and how they contact the body drive the evaluation — not a standard list of tests.
Six Disciplines That Carry a Biological Evaluation.
From the evaluation plan to the risk assessment that closes the endpoints without over-testing.
Biological Evaluation Plan
The BEP that frames the whole file: contact categorisation, materials, existing data, and the endpoint strategy — written before a single test is booked.
Chemical Characterization
ISO 10993-18 characterization that identifies extractables and leachables — the analytical foundation the modern evaluation is built on.
Toxicological Risk Assessment
The 10993-17 risk assessment that translates chemistry into safety conclusions — closing endpoints without a reflexive animal study.
Endpoint Justification
The reasoned case for which endpoints apply and which don’t — the justification a reviewer wants, in place of an over-run test battery.
Material & Supplier Change
Biocompatibility re-evaluated when a material, supplier, or process changes — the trigger that quietly reopens a closed file.
Biological Evaluation Report
The BER assembled to support the submission — plan, characterization, assessment, and conclusion, in the form FDA and Notified Bodies read.
Endpoints, chemistry, and hazards belong in one risk narrative — not three disconnected reports.
Biocompatibility Is a Branch of Risk Management, Not a Testing Line Item.
Because ISO 10993 sits inside the risk process, biocompatibility isn’t a box the lab ticks — it’s a set of conclusions your ISO 14971 risk file has to carry. Endpoints map to hazards; characterization data feeds the risk assessment; a material change is a risk event. Treat it as a standalone testing exercise and the file and the risk analysis drift apart.
We run the biological evaluation as part of the device’s risk management, so the endpoints, the chemistry, and the hazards stay one coherent story — the story a reviewer expects to be able to follow end to end.
Six Failure Modes We Are Brought In to Prevent.
Most are a test battery run where a plan and a risk assessment were needed.
Testing before planning
The lab booked before the Biological Evaluation Plan exists — and a spend that answers endpoints the risk assessment would have closed on paper.
No chemical characterization
Skipping ISO 10993-18 characterization — and losing the analytical foundation that lets a risk assessment stand in for testing.
Endpoints not justified
A battery run without the reasoning for which endpoints apply — the justification a reviewer asks for and the file doesn’t contain.
Biocompatibility outside the risk file
Evaluation run as a standalone exercise — so it never connects to the ISO 14971 hazards it’s supposed to address.
The unmanaged material change
A supplier or material change shipped without re-evaluation — and a biocompatibility conclusion that no longer describes the device.
Old-battery thinking
Defaulting to animal studies the modern, risk-based standard would answer with chemistry — slower, costlier, and increasingly out of step with expectations.
Biological Evaluation, Led by the Plan and the Risk Assessment.
Our leads have written evaluation plans, run characterization-led strategies, and closed endpoints through risk assessment.
“Biocompatibility isn’t a test battery you run — it’s a risk question you answer. Lead with the plan and the chemistry, and the animal studies you don’t need simply fall away.”
The discipline we bring to biological evaluation.
Choosing a Material — or Facing a Biocompatibility Gap? Start With the Plan.
A senior lead can build your Biological Evaluation Plan, lead with characterization, and close the endpoints through risk assessment — before a reflexive test battery sets the budget.
Senior-led. Embedded in your team. No junior hand-offs.